LDS/Medical Tests/Brugada Syndrome Multi-Gene Panel, NGS

Brugada Syndrome Multi-Gene Panel, NGS

Brugada syndrome (BRS) is an autosomal dominant inherited disorder affecting the function of proteins regulating cardiac ion channels. These changes in ion channel functions predispose affected individuals to cardiac arrhythmias and increased risk of syncope and sudden death. BRS has been linked to both sudden infant death syndrome (SIDS) as sudden unexplained nocturnal death syndrome (SUNDS).

The disease can manifest at any age, however, the mean age for sudden death is middle age (40s) and it affects more males than females. Patients with known BRS syndrome mutations may not have clinical symptoms, however, many patients experience repeated syncope and are at risk for sudden cardiac death due to polymorphic ventricular tachycardia and ventricular fibrillation.

The diagnosis of BRS is usually established based on EKG abnormalities along with personal and family history and requires exclusion of other causes including cardiac structural abnormalities, medications, and electrolyte imbalances. Since BRS is a genetic disorder, genetic testing for most common related mutations is now available to support the clinical diagnosis. Identification of a heterozygous (or hemizygous in the case of KCNE5 in a male) pathogenic variant in one of 23 genes: ABCC9, CACNA1C, CACNA2D1, CACNB2, FGF12, GPD1L, HCN4, KCND2, KCND3, KCNE5, KCNE3, KCNH2, KCNJ8, PKP2, RANGRF, SCN1B, SCN2B, SCN3B, SCN5A, SCN10A, SEMA3A, SLMAP, and TRPM4 is useful for confirming the diagnosis of BRS.

  • As an aid in diagnosis of Brugada syndrome

Positive results are reported as Pathogenic variants following ACMG recommendations as a guidelines with information on gene mutation, mutation position, change in amino acid and carrier status and gene classification. In addition, clinical interpretation should follow.

For example:
Gene: SCN5A (NM_198056.2)
Genomic position: g.38627386_38627387
Mutation: c.2582_2583delTT
Amino acid change: p.Phe861TrpfsX90
Carrier status: The patient is heterozygous for this variant

Classification: Pathogenic
Interpretation: The c.2582_2583delTT (p.Phe861TrpfsX90) variant in the SCN5A (NM_198056.2) gene is a known pathogenic variant.

The finding of a pathogenic variant is supportive of a diagnosis of Brugada syndrome for this individual but should be correlated with clinical findings.

Negative for mutations analyzed (Mutation not detected)

Target Next Generation Sequencing (NGS), Sanger sequencing.

Blood (EDTA). Buccal swab or saliva can be also used.

Stability

  • Ambient: 7 days
  • Refrigerated: 7-14 days
Cardiac Troponin-I/T, B-Type Natriuretic Peptide (BNP), Comprehensive metabolic panel, CBC.
7-14 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login